Including males in Canadian human papillomavirus vaccination programs: a policy analysis

201637 citationsJournal Articlegold Open Access

Authors

Gilla K. Shapiro · Jewish General Hospital

Zeev Rosberger · Jewish General Hospital

Abstract

The Canadian National Advisory Committee on Immunization (NACI) recommends human papillomavirus (HPV) vaccination for females aged 9–26 years (bivalent or quadrivalent vaccine) and males aged 9–26 years (quadrivalent vaccine) ([Figure 1][1]).[1][2] All Canadian provinces and territories

Topics & Keywords

Cervical Cancer and HPV Research Genital Health and Disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Canadian Medical Association Journal

Volume 188, Issue 12, pp. 881-886

DOI: 10.1503/cmaj.150451

Field-Weighted Citation Impact: 5.64